Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

The Implication of TP53 Allelic Status for Outcome and Erythropoiesis in MDS

Bing Li, Yanping Zeng, Chengwen Li, Jinqin Liu, Ge Song, Yao Yao, Amer M. Zeidan, Zhijian Xiao

Blood (2024) 144 (Supplement 1): 6707.

https://doi.org/10.1182/blood-2024-205429

Published: 2024

Journal Articles

Body Mass Index and Clinical Associations in Australasian Lymphoma Patients: A Lymphoma and Related Diseases Registry Study

Serif Sungur, Yao Yao, Cameron Wellard, Eliza Chung, Susan Morgan, Denise Lee, Geoffrey Chong, Chan Y. Cheah, Tasneem Rizvi, Eliza A. Hawkes, Zoe K McQuilten, Erica M. Wood, Nada Hamad, Tasman Armytage, Anna M. Johnston

Blood (2024) 144 (Supplement 1): 5126.

https://doi.org/10.1182/blood-2024-206277

Published: 2024

Journal Articles

Underweight Body Mass Index Is an Independent Risk Factor for Overall Survival in Diffuse Large B-Cell Lymphoma Treated with Rituximab, Prednisolone, Cyclophosphamide, Vincristine, and Doxorubicin: A Lymphoma and Related Diseases Registry Study

Yao Yao, Serif Sungur, Cameron Wellard, Eliza Chung, Susan Morgan, Denise Lee, Geoffrey Chong, Chan Y. Cheah, Eliza A. Hawkes, Erica M. Wood, Nada Hamad, Anna M. Johnston, Tasman Armytage

Blood (2024) 144 (Supplement 1): 2359.

https://doi.org/10.1182/blood-2024-202797

Published: 2024

Journal Articles

Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Blood (2024) 144 (Supplement 1): 4349.

https://doi.org/10.1182/blood-2024-202324

Published: 2024

Journal Articles

The Incidence, Clinical Application and Prognostic Significance of MYD88 and CXCR4 Mutation in Chinese Patients with Lymphoplasmacytic Lymphoma/ Waldenström Macroglobulinemia

Ying Yu, Yuting Yan, Jun Wang, Wenjie Xiong, Yao Yao, Yanshan Huang, Rui Lyu, Tingyu Wang, Qi Wang, Wei Liu, Gang An, Weiwei Sui, Yan Xu, Wenyang Huang, Dehui Zou, Zhijian Xiao, Lugui Qiu, Shuhua Yi

Blood (2023) 142 (Supplement 1): 6089.

https://doi.org/10.1182/blood-2023-188786

Published: 2023

Journal Articles

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

Blood (2023) 141 (23): 2841–2852.

https://doi.org/10.1182/blood.2022018885

Published: 2023

Includes: Supplemental data

Journal Articles

Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma

Ting Du, Yan Song, Arghya Ray, Xueping Wan, Yao Yao, Mehmet K. Samur, Chen Shen, Johany Penailillo, Tomasz Sewastianik, Yu-Tzu Tai, Mariateresa Fulciniti, Nikhil C. Munshi, Hao Wu, Ruben D. Carrasco, Dharminder Chauhan, Kenneth C. Anderson

Blood (2023) 141 (21): 2599–2614.

https://doi.org/10.1182/blood.2022017897

Published: 2023

Includes: Supplemental data

Journal Articles

Long Noncoding RNA LINC01410 Interacts with the Minichromosome Maintenance (MCM) Complex to Promote Tumor Cell Growth in Multiple Myeloma

Doriana Gramegna, Na Liu, Yao Yao, Megan Johnstone, Domenico Maisano, Annamaria Gulla, Anil Aktas-Samur, Aldo Roccaro, Mehmet K. Samur, Mariateresa Fulciniti, Eugenio Morelli, Nikhil C Munshi

Blood (2022) 140 (Supplement 1): 4191–4192.

https://doi.org/10.1182/blood-2022-169185

Published: 2022

Journal Articles

26S Proteasome Non-Atpase Subunit 1, PSMD1/Rpn2, Is a Potential Therapeutic Target in Multiple Myeloma

Ting Du, Xueping Wan, Arghya Ray, Yao Yao, Ruben D. Carrasco, Mariateresa Fulciniti, Nikhil C Munshi, Dharminder Chauhan, Kenneth C. Anderson

Blood (2022) 140 (Supplement 1): 8853–8854.

https://doi.org/10.1182/blood-2022-163749

Published: 2022

Journal Articles

CDK7 Inhibition Targets Proliferative and Metabolic Oncogenic Vulnerabilities in Multiple Myeloma

Yao Yao, Jessica Fong Ng, Woojun D Park, Mehmet K. Samur, Eugenio Morelli, Nicholas P Kwiatkowski, Jessica Encinas Mayoral, Zuzana Chyra, Yan Xu, Behnam Nabet, Marta Chesi, Nathaniel Gray, Richard A. Young, Kenneth C. Anderson, Charles Y Lin, Nikhil C Munshi, Mariateresa Fulciniti

Blood (2022) 140 (Supplement 1): 9955–9956.

https://doi.org/10.1182/blood-2022-163811

Published: 2022

Journal Articles

Dual BCL-2/BCL-XL Inhibitor Pelcitoclax (APG-1252) Overcomes Intrinsic and Acquired Resistance to Venetoclax in Multiple Myeloma Cells

Leona Yamamoto, Sanika Derebail, Anil Aktas-Samur, Teru Hideshima, Zuzana Chyra, Chandraditya Chakraborty, Yao Yao, Doriana Gramegna, Eugenio Morelli, Mehmet K. Samur, Jing Deng, Yifan Zhai, Annamaria Gulla, Mariateresa Fulciniti, Kenneth C. Anderson, Nikhil C. Munshi

Blood (2021) 138 (Supplement 1): 2655.

https://doi.org/10.1182/blood-2021-149530

Published: 2021

Journal Articles

B Cell Transcriptional Coactivator POU2AF1 (BOB-1) Is an Early Transcription Factor Modulating the Protein Synthesis and Ribosomal Biogenesis in Multiple Myeloma: With Therapeutic Implication

Zuzana Chyra, Mehmet K. Samur, Anil Aktas-Samur, Yao Yao, Sanika Derebail, Tommaso Perini, Yan Xu, Eugenio Morelli, Sophia Adamia, Woojun D Park, Lin Charles, Ryosuke Shirasaki, Masood A. Shammas, Constantine S. Mitsiades, Roman Hajek, Mariateresa Fulciniti, Nikhil C. Munshi

Blood (2021) 138 (Supplement 1): 2670.

https://doi.org/10.1182/blood-2021-152121

Published: 2021

Journal Articles

Transcriptional Deregulation Mediated By ID2-TCF3 Axis Supports MM Cell Growth and Proliferation in the Context of the Bone Marrow Milieu

Yao Yao, Tommaso Perini, Mehmet K. Samur, Raphael Szalat, Moritz Binder, Kenneth C. Anderson, Mariateresa Fulciniti, Nikhil C. Munshi

Blood (2021) 138 (Supplement 1): 2686.

https://doi.org/10.1182/blood-2021-152526

Published: 2021

Journal Articles

Universally Observed Loss of BCL7A Allows Activation of IRF4 and Its Transcriptional Activity in Multiple Myeloma Cells

Chandraditya Chakraborty, Srikanth Talluri, Eugenio Morelli, Sanika Derebail, Yao Yao, Yan Xu, Alba Rodríguez García, María Linares, Kenneth C. Anderson, Moritz Binder, Mehmet K. Samur, Mariateresa Fulciniti, Nikhil C. Munshi

Blood (2021) 138 (Supplement 1): 2667.

https://doi.org/10.1182/blood-2021-153462

Published: 2021

Journal Articles

Aberrant CDK7 Activity Drives the Cell Cycle and Transcriptional Dysregulation to Support Multiple Myeloma Growth: An Attractive Molecular Vulnerability

Yao Yao, Woojun D Park, Eugenio Morelli, Mehmet K. Samur, Nicholas P Kwiatkowski, Ryosuke Shirasaki, Yan Xu, Chandraditya Chakraborty, Behnam Nabet, Marta Chesi, Nathaniel Gray, Richard A. Young, Kenneth C. Anderson, Constantine S. Mitsiades, Lin Charles, Nikhil C. Munshi, Mariateresa Fulciniti

Blood (2021) 138 (Supplement 1): 2687.

https://doi.org/10.1182/blood-2021-153469

Published: 2021

Journal Articles

RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-142514

Published: 2020

Journal Articles

Activation of the ERK Pathway Drives Acquired Resistance to Venetoclax in MM Cell Models

Chandraditya Chakraborty, PhD, Yan Xu, MD, Yao Yao, Eugenio Morelli, MD, Anil Aktas-Samur, PhD, Mehmet Kemal Samur, PhD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD, Kenneth Anderson, MD, Chandraditya Chakraborty, PhD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-142655

Published: 2020

Journal Articles

Enhancing the Immune Surveillance in Multiple Myeloma Via CDK4/6 Inhibition

Yan Xu, MD, Yao Yao, Woojun Daniel Park, Sanika Derebail, MS, Chandraditya Chakraborty, PhD, Shidai Mu, Rafael Alonso Fernández, Srikanth Talluri, PhD, Zuzana Chyra, PhD, Kenneth Wen, Qingsheng Yan, Osasenaga Idahor, Selene Cipri, Rao Prabhala, Kenneth Anderson, MD, Mehmet K. Samur, PhD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-143327

Published: 2020

Journal Articles

Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition

Yao Yao, Woojun D Park, Eugenio Morelli, MD, Mehmet Kemal Samur, PhD, Nicholas P Kwiatkowski, PhD, Yan Xu, MD, Chandraditya Chakraborty, PhD, Behnam Nabet, PhD, Marta Chesi, PhD, Herve Avet-Loiseau, Nathaniel Gray, Richard A. Young, PhD, Kenneth Anderson, MD, Charles Y Lin, PhD, Nikhil C. Munshi, MD, Mariateresa Fulciniti, PhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-142592

Published: 2020

Journal Articles

Disruption of the m-SWI/SNF Complex Mediated By Recurrent Non-Coding Mutations in BCL7A Induces Tumor Cell Proliferation in Multiple Myeloma

Chandraditya Chakraborty, PhD, Eugenio Morelli, MD, Srikanth Talluri, PhD, Sanika Derebail, MS, Yan Xu, MD, Yao Yao, María Linares, Alba Rodríguez García, Kenneth Anderson, MD, Mehmet Kemal Samur, PhD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-142178

Published: 2020

NARROW

The Implication of TP53 Allelic Status for Outcome and Erythropoiesis in MDS

Body Mass Index and Clinical Associations in Australasian Lymphoma Patients: A Lymphoma and Related Diseases Registry Study

Underweight Body Mass Index Is an Independent Risk Factor for Overall Survival in Diffuse Large B-Cell Lymphoma Treated with Rituximab, Prednisolone, Cyclophosphamide, Vincristine, and Doxorubicin: A Lymphoma and Related Diseases Registry Study

Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

The Incidence, Clinical Application and Prognostic Significance of MYD88 and CXCR4 Mutation in Chinese Patients with Lymphoplasmacytic Lymphoma/ Waldenström Macroglobulinemia

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma

Long Noncoding RNA LINC01410 Interacts with the Minichromosome Maintenance (MCM) Complex to Promote Tumor Cell Growth in Multiple Myeloma

26S Proteasome Non-Atpase Subunit 1, PSMD1/Rpn2, Is a Potential Therapeutic Target in Multiple Myeloma

CDK7 Inhibition Targets Proliferative and Metabolic Oncogenic Vulnerabilities in Multiple Myeloma

Dual BCL-2/BCL-XL Inhibitor Pelcitoclax (APG-1252) Overcomes Intrinsic and Acquired Resistance to Venetoclax in Multiple Myeloma Cells

B Cell Transcriptional Coactivator POU2AF1 (BOB-1) Is an Early Transcription Factor Modulating the Protein Synthesis and Ribosomal Biogenesis in Multiple Myeloma: With Therapeutic Implication

Transcriptional Deregulation Mediated By ID2-TCF3 Axis Supports MM Cell Growth and Proliferation in the Context of the Bone Marrow Milieu

Universally Observed Loss of BCL7A Allows Activation of IRF4 and Its Transcriptional Activity in Multiple Myeloma Cells

Aberrant CDK7 Activity Drives the Cell Cycle and Transcriptional Dysregulation to Support Multiple Myeloma Growth: An Attractive Molecular Vulnerability

RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma

Activation of the ERK Pathway Drives Acquired Resistance to Venetoclax in MM Cell Models

Enhancing the Immune Surveillance in Multiple Myeloma Via CDK4/6 Inhibition

Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition

Disruption of the m-SWI/SNF Complex Mediated By Recurrent Non-Coding Mutations in BCL7A Induces Tumor Cell Proliferation in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only